β-Blockers and angiotensin-converting enzyme inhibitors with sublingual immunotherapy: Are risks related to individual product safety profile?

Derek M. Smith*, Christopher A. Coop, Theodore M. Freeman

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

3 Scopus citations

Abstract

Purpose of reviewThe objective of this article is to review the available literature regarding the risks associated with sublingual immunotherapy and angiotensin-converting enzyme (ACE) inhibitors or β-blocker use. It also evaluates for any differences in these risks among the available sublingual immunotherapy (SLIT) tablets.Recent findingsA literature search was conducted in PubMed to identify peer-reviewed articles using the following keywords: anaphylaxis, ACE inhibitor, β-blocker, and sublingual immunotherapy. Minimal data exist regarding their safety of SLIT in patients concomitantly taking ACE inhibitors or β-blockers. The adverse reaction rates seem similar between SLIT products.SummaryA risk-versus-benefit discussion should be communicated with the patient taking a β-blocker before beginning SLIT but automatic denial of SLIT to these patients is not warranted.

Original languageEnglish
Pages (from-to)401-406
Number of pages6
JournalCurrent opinion in allergy and clinical immunology
Volume20
Issue number4
DOIs
StatePublished - 1 Aug 2020
Externally publishedYes

Keywords

  • anaphylaxis
  • angiotensin-converting enzyme inhibitor
  • sublingual immunotherapy
  • β-blocker

Fingerprint

Dive into the research topics of 'β-Blockers and angiotensin-converting enzyme inhibitors with sublingual immunotherapy: Are risks related to individual product safety profile?'. Together they form a unique fingerprint.

Cite this